Domov › Ploščatocelični karcinom glave in vratu › Utah
Klinične študije za Ploščatocelični karcinom glave in vratu v Utah
21 študij za Ploščatocelični karcinom glave in vratu išče udeležence na lokacijah v Utah.
Mesta v Utah
Uradno besedilo študije (angleško)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Farmington Health Center, Farmington
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06992427A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06465069A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 4, West Valley City
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07085091BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Huntsman Cancer Institute, Salt Lake City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Utah Huntsman Cancer Institute, Salt Lake City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06385080Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT05267626A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- START Center for Cancer Research, West Valley City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07109726ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT05059444Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 13. avg. 2026 · NCT05985655A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 11. avg. 2026 · NCT06242470A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT06330064A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Utah Cancer Specialists, Salt Lake City
- University of Utah Health Huntsman Cancer Hospital, Salt Lake City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT05208762First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 7. jul. 2026 · NCT05768139Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. jun. 2026 · NCT05005403A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- START Mountain Region, LLC, West Valley City
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 18. jun. 2026 · NCT07503808Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 10. jun. 2026 · NCT07517198Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 27. feb. 2026 · NCT07044635Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 18. feb. 2026 · NCT07030257VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Utah Cancer Specialists (site 203), Salt Lake City
Vključevanje udeležencevFaza 1/2
Starost 18–80 · Vsi spoli · Posodobljeno 11. dec. 2025 · NCT03556228Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.